On Thursday, 8 September 2022 the Novo Nordisk Foundation will host a workshop with the aim of bringing together the research community for an exciting day of knowledge sharing and networking, with the ambition to facilitate research partnerships and lay the seeds for realising creative solutions and new technologies within the 2023 Challenge Programme theme:
RNA and oligonucleotide-based therapeutics.
At the workshop there will be exciting invited and short talks as well as a poster session and participants can enjoy nice food and networking.
Please indicate at registration if you are bringing a poster and whether you would like to be selected for a short talk. Short talks will be selected based on submitted poster abstracts.
2023 Challenge: RNA and Oligonucleotide-based Therapeutics
With the overall aim of facilitating development of RNA/oligonucleotide-based therapeutics beyond treatment of rare diseases and vaccine purposes, the challenge is to develop novel RNA/oligonucleotide-based therapeutics for common clinical conditions, primarily cardiometabolic diseases, efficiently targeting the relevant tissue, cell types and subcellular localisation. An additional challenge will be to develop therapeutics that will allow direct and sufficient overexpression of proteins and peptides.
The research includes but is not limited to:
Research on cellular targeting to optimise delivery into specific cell types, such as adipocytes, endothelia or skeletal muscles, and control of subcellular localisation. This may include studies on chemical modification of RNA and oligonucleotides, development of nanoparticles, and cellular adaptation to RNA/oligonucleotide exposure.
Research that encourages development of novel RNA/oligonucleotide-based therapeutics and explores mechanisms to obtain increased transcription and protein expression.
Research that pursues therapeutics in novel RNA/oligonucleotide-based modalities such as aptamers, circular RNA, miRNA, and lncRNA.
Research in cellular response and adaptation to the RNA and oligonucleotides.